GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'

GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 shows the UK group remains a serious contender in the innovative cancer space, its oncology R&D head tells Scrip.

Myeloma
GSK's monoclonal ADC GSK2857916 wins FDA breakthrough status in multiple myeloma • Source: Shutterstock

GlaxoSmithKline PLC’s first-in-class anti-BCMA antibody-drug conjugate – which now has breakthrough therapy designation in the US for relapsed and refractory multiple myeloma – "serves notice that GSK is truly back in the oncology business", its divisional R&D head said in an interview.

GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By 

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By 

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

More from R&D

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By 

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.